We are live on ! Find out more
SCM

Silverarc Capital Management Portfolio holdings

AUM $962M
1-Year Est. Return 524.64%
This Fund
S&P 500
This Quarter Est. Return
+132.32%
1 Year Est. Return
+524.64%
3 Year Est. Return
+2,765.44%
5 Year Est. Return
+10,523.08%
10 Year Est. Return
–
AUM
$742M
AUM Growth
+$199M
Cap. Flow
+$28.6M
Cap. Flow %
3.86%
Top 10 Hldgs %
43.53%
Holding
99
New
34
Increased
28
Reduced
16
Closed
17

Top Buys

Rank Stock Value
1
ABVX
Abivax
ABVX
+$33.1M
2
RNAM
Avidity Biosciences
RNAM
+$17.6M
3
DNTH icon
Dianthus Therapeutics
DNTH
+$14.8M
4
GUTS icon
Fractyl Health
GUTS
+$13.5M
5
BIIB icon
Biogen
BIIB
+$10.9M

Top Sells

Rank Stock Value
1
MRUS
Merus
MRUS
+$39M
2
VRNA
Verona Pharma
VRNA
+$33.9M
3
NBIX icon
Neurocrine Biosciences
NBIX
+$20.5M
4
ETNB
89bio
ETNB
+$20M
5
SLNO
Soleno Therapeutics
SLNO
+$17.1M

Sector Composition

Rank Sector Weight
1 Healthcare 93.14%
2 Miscellaneous 6.86%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ABVX
1
Abivax
ABVX
$9.89B
$45.8M 6.18%
+539,704
New +$33.1M
RYTM icon
2
Rhythm Pharmaceuticals
RYTM
$7.38B
$37.4M 5.04%
369,996
-30,776
-8% -$2.86M
RNAM
3
DELISTED
Avidity Biosciences
RNAM
$36.8M 4.96%
844,633
+434,633
+106% +$17.6M
NUVL
4
DELISTED
Nuvalent
NUVL
$32.2M 4.34%
372,300
+136,717
+58% +$10.8M
URGN icon
5
UroGen Pharma
URGN
$2.13B
$31.5M 4.24%
1,577,283
-445,199
-22% -$7.99M
AKRO
6
DELISTED
Akero Therapeutics
AKRO
$30.6M 4.12%
643,636
-70,175
-10% -$3.4M
INSM icon
7
Insmed
INSM
$25.9B
$29.8M 4.01%
206,648
-42,412
-17% -$5.2M
DNTH icon
8
Dianthus Therapeutics
DNTH
$5.92B
$26.6M 3.58%
674,966
+579,160
+605% +$14.8M
QURE icon
9
uniQure
QURE
$3.38B
$26.6M 3.58%
455,000
+252,435
+125% +$4.58M
CGON icon
10
CG Oncology
CGON
$6.59B
$25.7M 3.47%
638,346
+97,312
+18% +$2.83M
UTHR icon
11
PUT
United Therapeutics
UTHR
$22.1B
$25.1M 3.39%
+59,900
New +$20.1M
ORIC icon
12
Oric Pharmaceuticals
ORIC
$1.37B
$23.4M 3.15%
1,948,808
+147,979
+8% +$1.56M
CDTX
13
DELISTED
Cidara Therapeutics
CDTX
$21.2M 2.85%
220,902
+116,959
+113% +$7.46M
GUTS icon
14
Fractyl Health
GUTS
$105M
$16.9M 2.27%
10,600,000
+10,397,410
+5,132% +$13.5M
KALV
15
DELISTED
KalVista Pharmaceuticals
KALV
$16.6M 2.24%
1,363,378
-468,793
-26% -$6.48M
KOD icon
16
Kodiak Sciences
KOD
$2.37B
$16.4M 2.21%
1,000,000
+598,460
+149% +$5.16M
RARE icon
17
CALL
Ultragenyx Pharmaceutical
RARE
$2.52B
$15.9M 2.14%
+528,200
New +$15.8M
GOSS icon
18
Gossamer Bio
GOSS
$83.2M
$12.6M 1.69%
4,779,082
-367,700
-7% -$810K
COGT icon
19
Cogent Biosciences
COGT
$6.02B
$11.7M 1.58%
+815,075
New +$9.66M
CYTK icon
20
Cytokinetics
CYTK
$10B
$11.6M 1.56%
+211,000
New +$8.69M
PCVX icon
21
Vaxcyte
PCVX
$8.9B
$11.3M 1.53%
314,339
+26,543
+9% +$879K
BIIB icon
22
Biogen
BIIB
$32.3B
$11.3M 1.52%
+80,419
New +$10.9M
ASND icon
23
Ascendis Pharma A/S
ASND
$16.3B
$10.6M 1.44%
53,554
-32,998
-38% -$6.15M
CMPX icon
24
Compass Therapeutics
CMPX
$432M
$9.92M 1.34%
2,833,988
+1,584,207
+127% +$5M
AMLX icon
25
Amylyx Pharmaceuticals
AMLX
$3.87B
$9.51M 1.28%
+700,000
New +$6.59M
1
2 3 4

Similar funds

LGP
Leonard Green & Partners Los Angeles, California $962M AUM 35.11% 1-Year Est. Return
PL
Parthenon LLC Louisville, Kentucky $962M AUM 27.46% 1-Year Est. Return
LAM
L2 Asset Management Wayland, Massachusetts $963M AUM 38.06% 1-Year Est. Return
ACP
Aviance Capital Partners Naples, Florida $963M AUM 32.56% 1-Year Est. Return
GIG
Goodnow Investment Group Darien, Connecticut $964M AUM 2.51% 1-Year Est. Return
AAP
Ardsley Advisory Partners Stamford, Connecticut $960M AUM 207.76% 1-Year Est. Return
BEAM
Baker Ellis Asset Management Vancouver, Washington $964M AUM 39.24% 1-Year Est. Return
RAM
Ramirez Asset Management New York $960M AUM 30.25% 1-Year Est. Return

Silverarc Capital Management's Q3 2025 Portfolio in Review

As of Q3 2025, Silverarc Capital Management held 99 positions worth $742M, up 37% from $542M the previous quarter. Its ten largest holdings account for 44% of the portfolio.

Silverarc Capital Management deployed $28.6M of net new capital in Q3 2025, opening 34 new positions and adding to 28 existing holdings. Its largest new stake was Abivax: 539,704 shares worth $45.8M.

By sector, the portfolio is most concentrated in Healthcare at 93% of assets, up from 90% a quarter earlier, followed by Miscellaneous.

On the sell side, the largest reduction was UroGen Pharma, an estimated $7.99M trimmed.

  • Silverarc Capital Management's largest Q3 2025 buy was Abivax: 539,704 shares worth $45.8M.
  • Silverarc Capital Management added most to Avidity Biosciences in Q3 2025, an estimated $17.6M increase.
  • Silverarc Capital Management's biggest Q3 2025 reduction was UroGen Pharma, cutting an estimated $7.99M.
  • Silverarc Capital Management fully exited Merus in Q3 2025, selling an estimated $39M.
  • Silverarc Capital Management's ten largest holdings make up 44% of its $742M portfolio in Q3 2025.
  • Silverarc Capital Management opened 34 new positions and closed 17 in Q3 2025.
  • Silverarc Capital Management's portfolio value rose 37% quarter-over-quarter to $742M.

Based on Silverarc Capital Management's 13F filing for Q3 2025, filed 12 Nov 2025.